ClinicalTrials.gg
CompletedNCT00696202Updated Dec 31, 2014

Mirena Efficiency and Tolerability During the First Year of Use

A Phase 4 interventional study of Mirena (BAY86-5028) in Medicated Intrauterine Devices and Contraception, sponsored by Bayer. Completed at 1 site in France. Open to female participants aged 25 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-12-31.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
199
Allocation
Non-randomized
Ages
25 Years to 39 Years
Sex
Female
01

Study summary

In this trial the efficacy and safety of Mirena was investigated during the first year of use

02

Conditions studied

  • Medicated Intrauterine Devices
  • Contraception

Keywords

  • Mirena
  • Levonorgestrel
  • Intrauterine device
  • Efficacy
  • Tolerability
  • First year of use
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 25 to 39 years who sought effective during the post-partum period (i.e. insertion of the device between 6 and 12 weeks after parturition).

Exclusion criteria

Exclusion Criteria:

  • Standard exclusion criteria for use of intrauterine hormone devices
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Mirena (BAY86-5028)

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse event related to the product causing a subject to withdraw, or be withdrawn, from the study at any time up to 12 months from the insertion of Mirena

    Time frame: within 12 months after randomization

Secondary outcomes

  1. General safety assessment

    Time frame: within 12 months after randomization

07

Study locations

1 site
  • Amiens Cedex 01, 80054, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2008
First posted
Jun 12, 2008
Start
Sep 2003
CompletionActual
Mar 2005
Last update
Dec 31, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00696202
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 12, 2008
Start date
Sep 2003
Completion
Mar 2005
Last update
Dec 31, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levonorgestrel

Start the discussion